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Methods This was an observational study con‑
ducted in 2012 at the Department of Cardiovas‑
cular Surgery and Transplantology, Institute of 
Cardiology, Jagiellonian University Medical Col‑
lege (Kraków, Poland). We included 76 consecu‑
tive patients referred for coronary artery bypass 
grafting (CABG) due to stable CAD. The only ex‑
clusion criterion was a referral for an urgent pro‑
cedure. All patients provided written informed 
consent to participate in the study, and the study 
was approved by the Jagiellonian University Eth‑
ics Committee.
Patients were screened for typical risk fac‑
tors of atherosclerosis and history of myocar‑
dial infarction. Coronary angiograms were ana‑
lyzed and the Gensini score was used for a quan‑
titative analysis of coronary atherosclerosis.9
Parvovirus B19 diagnostics Venous blood 
was collected before CABG, centrifuged, and 
the supernatants were stored at a temper‑
ature of –80°C. The  level of anti–parvovi‑
rus B19 IgG antibodies was measured using 
an enzyme ‑linked immunosorbent assay (re-
comWell Parvovirus B19 IgG kit; Mikrogen Di‑
agnostik, Neuried, Germany). Based on the re‑
sults, patients were divided into a group pos‑
itive for anti–parvovirus B19 IgG antibodies 
(patients who have suffered the infection) 
and a group negative for anti–parvovirus B19 
IgG antibodies (patients with no evidence of 
the infection).
Statistical analysis Normal distribution 
of continuous variables was assessed using 
the Shapiro–Wilk test. For the association of 
Introduction Besides the well ‑established risk 
factors for the development of coronary athero‑
sclerosis, such as sex, hypertension, dyslipidem‑
ia, diabetes, and smoking, there have been stud‑
ies showing a correlation between infections and 
coronary artery disease (CAD). There is a sub‑
stantial amount of data suggesting a possible in‑
volvement of Chlamydophila pneumoniae,1 herpes 
simplex virus 2,2 cytomegalovirus,3 Helicobacter 
pylori,4 or Porphyromonas gingivalis5 in the devel‑
opment or exacerbation of atherosclerosis. It is 
postulated that they might exert an atherogenic 
effect by causing systemic proinflammatory con‑
ditions. Nevertheless, none of the above patho‑
gens targets the human endothelium.1 One path‑
ogen with direct tropism for human endothelial 
cells is parvovirus B19, which has been shown 
not only to infect endothelial cells but also to im‑
pair their regeneration.6 Since atherosclerosis is 
strongly dependent on endothelial dysfunction, 
this suggests that parvovirus B19 could be in‑
volved in plaque development. Parvovirus B19 
infections are common. An epidemiologic study 
indicated that a parvovirus B19 infection has af‑
fected 80% of the Polish population at the age 
of 40 years.7 Clinical presentations of the infec‑
tion range from erythema infectiosum in chil‑
dren to arthropathy or myocarditis in adults, 
with a suggested involvement in the pathogen‑
esis of rheumatic diseases. However, a parvovi‑
rus B19 infection may often be asymptomatic or 
show influenza ‑like symptoms only.8
The aim of this study was to determine wheth‑
er there is an association between anti–parvovi‑
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cardiac death, myocardial infarction, and clin‑
ically driven target lesion revascularization.
Parvovirus B19 genetic material can be found 
in cells in a quiescent state, at levels that do not 
exert an immune response.13 It has been dem‑
onstrated that a simultaneous infection with 
parvovirus B19 and adenoviruses can augment 
the expression of parvovirus B19 proteins with‑
in endothelial cells.14 Therefore, it is possible that 
an isolated parvovirus B19 infection of the en‑
dothelium does not have the potency to lead to 
a clinically relevant effect on atherosclerosis 
and requires a coinfection with other viruses.
Parvovirus B19 material can be found 
in around 1% of patients with myocarditis.15 Still, 
none of the patients in our group had a histo‑
ry of myocarditis. This might be due to the fact 
that most parvovirus B19 infections are asymp‑
tomatic or display influenza ‑like symptoms and 
may have been missed. Since the median age of 
patients was above 60 years and myocarditis 
usually affects individuals aged 20 to 40 years 
old, it is possible that some myocardial infec‑
tions had occurred in the parvovirus B19–pos‑
itive group in the distant past and were not di‑
agnosed at the time of presentation.
In conclusion, our results show that pa‑
tients positive for anti–parvovirus B19 anti‑
bodies had a larger atherosclerotic burden mea‑
sured by the Gensini score and were more like‑
ly to have suffered from a myocardial infarc‑
tion than seronegative patients. However, this 
was a preliminary study on a small group of pa‑
tients. Therefore, conclusions must be inter‑
preted with caution and should be confirmed 
in a larger population. Still, as arterial endo‑
thelial cell dysfunction underlies the develop‑
ment of atherosclerosis, it seems that the asso‑
ciation between parvovirus B19 infection and 
CAD is an interesting research field.
nominal variables, the Pearson χ2 test was used. 
The Mann–Whitney test was used in the case 
of one nominal and one continuous variable 
(no continuous variables showed a normal dis‑
tribution in any of the groups). A P value of less 
than 0.05 was considered significant.
Results and discussion Of the 76 patients, 
63 tested positive for the presence of parvovi‑
rus B19 IgG antibodies (82.9%), which is consis‑
tent with epidemiologic data.7 The distribution 
of risk factors for CAD was typical and did not 
differ between seropositive and seronegative pa‑
tients. We found that seropositive patients were 
more likely to have a history of myocardial in‑
farction (36.5% vs 7.7%, P = 0.049). We also ob‑
served a larger atherosclerotic burden in the se‑
ropositive than in the seronegative group (Gen‑
sini score, 98 vs 70, P = 0.049). Detailed results 
are presented in TABLE 1.
Based on the assessed indicators of CAD se‑
verity, it seems plausible that a parvovirus B19 
infection may influence the development of 
coronary atherosclerosis. Since one of the first 
stages and hallmarks of atherosclerosis is endo‑
thelial dysfunction, it is possible that infectious 
agents targeting the endothelium and causing 
inflammation, such as parvovirus B19, might 
contribute to the development of atherosclerot‑
ic plaques. This hypothesis is in fact supported 
by published data.10 Liu et al11 performed a se‑
rology analysis of 565 individuals with CAD 
and healthy controls and demonstrated that pa‑
tients with CAD were significantly more often 
positive for anti–parvovirus B19 IgG antibodies 
than controls. An interesting study by Niccoli 
et al12 showed that the presence of parvovirus 
B19 DNA on a balloon used to predilate coro‑
nary lesions was a predictor of major adverse 
cardiovascular events defined as a composite of 
TABLE 1 Characteristics of patients with seropositivity and seronegativity for anti–parvovirus B19 immunoglobulin G antibodies
Parameter Seropositive patients (n = 63) Seronegative patients (n = 13) P value
Age, y, median (min–max; IQR) 63 (47–80; 14) 62 (51–82; 18) 0.65a
Sex, male, n (%) 51 (81.0) 10 (77.0) 0.40b
Hypertension, n (%) 50 (79.4) 13 (100.0) 0.40b
Dyslipidemia, n (%) 44 (69.8) 11 (84.6) 0.57b
Diabetes, n (%) 22 (34.9) 4 (30.8) 0.12b
Active smoking, n (%) 38 (60.3) 8 (61.5) 0.84b
Preprocedural LVEF, median (min–max; IQR) 52 (35–70; 6) 52 (40–70; 6) 0.91a
History of MI, n (%) 23 (36.5) 1 (7.7) 0.049b
Gensini score, median (min–max; IQR) 98 (46.5–152.5; 33.5) 70 (45–134; 38) 0.049a
a Mann–Whitney test; b  χ2 test
Abbreviations: IgG, immunoglobulin G; IQR, interquartile range; max, maximum; MI, myocardial infarction; min, minimum; LVEF, left ventricular ejection fraction
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